Leveraging Old Hepatitis C Therapies | NEJM
Older drugs could potentially advance U.S. hepatitis C elimination efforts. The government could act like a business and use all current and historical market information to its advantage.
Related Articles
Out of Pocket Getting Out of Hand — Reducing the Financial Toxicity of Rapidly Approved Drugs | NEJM
The FDA often exercises flexibility in deciding whether to approve highly promising drugs for patients in desperate need of treatment options. But it doesn’t consider…
Acalabrutinib Combinations in Chronic Lymphocytic Leukemia | NEJM
Quick Take Video Summary from The New England Journal of Medicine — Acalabrutinib Combinations in Chronic Lymphocytic Leukemia
What drives differences in life expectancy between the U.S. and comparable countries? – Peterson-KFF Health System Tracker
The United States spends more on health care than any similarly large and wealthy country. However, in 2023, Americans had a life expectancy of 78.4…
The Duration of Immunotherapy for Mismatch Repair–Deficient Cancers | NEJM
An analysis of published studies suggests that a longer duration of immune checkpoint inhibitor therapy is associated with a higher incidence of complete response among…
Monoclonal Antibodies in Eosinophilic COPD Safely Reduce Exacerbations
Treating eosinophilic COPD with monoclonal antibodies significantly reduces exacerbations vs standard care, with an acceptable safety profile.
February 20, 2025 | NEJM
Image Challenge from the New England Journal of Medicine — February 20, 2025
The Medicare conversion factor: What is it and why is it punishing physicians? – CHEST Physician
This year’s final rule from CMS provided the long-expected but unwelcome news of a 2.8% cut in the 2025 Medicare conversion factor.
Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia | NEJM
Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress…
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease | NEJM
In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk…